BioSpace News Archive

eFFECTOR Therapeutics, Inc. today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer.

The National Comprehensive Cancer Network® announced publication of new NCCN Guidelines for Patients®: Small Bowel Adenocarcinoma.

The Beyeonics™ Maverick system has been used in surgery for the first time to successfully give surgeons enhanced visual and operational capabilities during neurosurgical and orthopedic procedures.

AIM ImmunoTech Inc. announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.

Ferring Pharmaceuticals today announced three poster presentations at Digestive Disease Week® (DDW 2024) that add to the robust clinical evidence for REBYOTA® (fecal microbiota, live – jslm), including the first real-world outcomes data assessing the use of this therapy in patients with recurrent C. difficile (C. diff) infection.

“Number Of Commercially Approved Bispecific Antibodies Will Be More Than 20 Antibodies By 2030 From 12 Approved Bispecific Antibodies In First Quarter Of 2024”

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has completed its analysis of its spring spider silk production trials

Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI).

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the U.S. Patent and Trademark Office (USPTO) granted US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”.

Biocom California, the association representing the California life science industry, released a new report showing California’s life science industry directly provides more than 465,000 jobs in the state and generates $414.2 billion in total business output.